USPTO serial 98887218
ACCELSIORS
Reviewed by CopyMark Law Group
Status 748
- Filing date
- Status date
- Registration date
- —
- Examiner
- BUONGIORNO, CHRISTOPHER L
- Law office
- TMEG LAW OFFICE 101
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ACCELSIORS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Scott M. Sisun, Esq.
Scott M. Sisun, Esq. Sisun Law135 Madison Avenue, Floor 5New York, NY 10016United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Market analysis and research services; Business marketing consulting; Marketing consulting; Business consulting and information services; Business consulting services and business management consulting in the pharmaceutical field; Business process outsourcing services, namely, providing project management for others for business purposes in the pharmaceutical field; Business process outsourcing services, namely, providing business analysis and business data compilation relating to the operational feasibility of clinical trial sites for clinical study and clinical study protocol feasibility in the pharmaceutical field; Computerized database management and data processing services in the pharmaceutical field; Independent sales representatives in the pharmaceutical field; Business consultation and management regarding marketing activities, launching of new products and services, and sales; Personnel recruitment and placement; Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of pharmaceutical companies to assist them with clinical research, clinical trials and applications for drug, biologic and medical device approval; Providing independent review of clinical trials for business purposes; Maintaining a registry of patients; Business consulting and business management consultation services related to healthcare management and electronic health records management; Business management consulting and advisory services in pharmaceutical field; Advertising, marketing and promotional services in the nature of creating and placing online advertisements on websites to promote and recruit participants for clinical studies in the pharmaceutical field; Business management services, namely, quality management services for establishing business quality policies for patient-care programs; Recruitment advertisement services, namely, posting of clinical trial notices for the purpose of recruiting patients for participation in clinical trials for the testing of drugs, biologics and devices; Business consulting in the field of healthcare management | ACTIVE | Jun 1, 2022 |
| 041 | Education and training services, namely, conducting training programs, seminars, classes, conferences and workshops in the pharmaceutical field; Educational and training services, namely, conducting conferences to train physicians and other medical providers on conducting clinical trials; Education and training services, namely, providing non-downloadable webinars, webcasts and podcasts in the pharmaceutical field; Non-downloadable online publications in the nature of brochures, reports, or white papers in the pharmaceutical field; education services, namely, individual training and classes for training of patients, physicians and other healthcare providers on disease and disease treatment management | ACTIVE | Jun 1, 2022 |
| 042 | Providing an online content-based portal that provides medical research information in the field of pharmaceuticals; Providing medical and scientific research information in the fields of pharmaceuticals, biotechnologies, and healthcare; Providing online, non-downloadable software providing pharmaceutical, medical, and healthcare information and analysis; Software as a service (SAAS) services featuring software for providing, collecting, analyzing pharmaceutical, medical, healthcare, and clinical information; Computer services, namely, providing on-line, non-downloadable computer software used for accessing, collecting, managing, tracking, analyzing, and reporting clinical data in the pharmaceutical field; Research in the field of pharmaceuticals; Computer services, namely, designing, developing and maintaining application software in the fields of pharmaceutical, medical, and healthcare clinical information; Computer software development for others; Clinical research, clinical research testing of drugs, vaccines, medical devices, and biological products used in the medical industry, and laboratory testing services of blood samples and human tissues in the pharmaceutical field; Product development consultation in the pharmaceutical field; Medical and scientific research, namely, conducting clinical trials for others; Providing temporary use of on-line non-downloadable software for use in healthcare, namely, software for electronic trial master file (eTMF) management that enables the storage, organization, retrieval, and secure access of clinical trial documentation and electronically signed records and electronic health record management; Information technology consulting services relating to installation, maintenance and repair of computer software; Computer software consultation services in the pharmaceutical field; Scientific research in the pharmaceutical, medical, and healthcare field; Computer services, namely, creating computer network-based indexes and databases of information in the fields of pharmaceutical, medical, and healthcare; Providing temporary use of online, non-downloadable software for collection and management of healthcare and pharmaceutical data; Providing temporary use of online, non-downloadable computer software for collecting, managing, and analyzing clinical trial data; Providing an on-line interactive database featuring scientific research information in the pharmaceutical field; Providing medical and scientific research information relating to the development, and validation of drugs, biologics and devices, namely, information in the field of new product development and product testing | ACTIVE | Jun 1, 2022 |
| 044 | Providing medical information relating to the development, and validation of drugs, biologics and devices; Providing health, medical, and disease management information to others | ACTIVE | Jun 1, 2022 |
| 045 | Legal research in the field of public policy; Providing legal information relating to the development, and validation of drugs, biologics and devices, namely, legal information in the field of new product development and product testing; Regulatory compliance legal research in the field of development and testing of drugs, devices, biologics and methodologies used in the pharmaceutical industry, biotechnology industry and the medical and diagnostics industry; Regulatory compliance consulting in the pharmaceutical, medical, and healthcare fields; Providing regulatory information, namely, legal information regarding compliance with pharmaceutical, medical, and healthcare regulations; Providing regulatory services, namely, regulatory compliance consulting in the fields of development, validation, and production of drugs, biologics and medical devices | ACTIVE | Jun 1, 2022 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Accelsiors AG
- Other trademarks owned by Accelsiors AG
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named ACCELSIORS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 4, 2026 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Oct 28, 2026 | IUAF | USE AMENDMENT FILED | — |
| Oct 28, 2026 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Apr 28, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Mar 3, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 3, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Feb 25, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 7, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 17, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 17, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 17, 2026 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Dec 18, 2025 | GNS1 | NOTIFICATION OF SUBSEQUENT FINAL EMAILED | — |
| Dec 18, 2025 | GNCF | CONTINUATION OF FINAL REFUSAL E-MAILED | — |
| Dec 18, 2025 | CNCF | ACTION CONTINUING A FINAL - COMPLETED | — |
| Dec 5, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 5, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 5, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Sep 5, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Sep 5, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Sep 5, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 25, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 25, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 25, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 27, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 27, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 27, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 26, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 27, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 5, 2024 | NWAP | NEW APPLICATION ENTERED | — |